Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)

November 4, 2011 · Filed Under analyst calls, Cancer, Diabetes, Heart, obesity · 19 Comments 

Vical Inc. (NASDAQ: VICL) and VIVUS, Inc. (NASDAQ: VVUS) are both running higher this Friday on news that Credit Suisse initiated both biotech outfits with “Outperform” ratings.  What matters more than the call are the price targets and the inferences made in the research calls.

Vical Inc. (NASDAQ: VICL) is rarely given huge analyst calls due to what is a small $250 million or so in market cap.  The team at Credit Suisse initiated Vical with an “Outperform” rating this morning but more important is its price target of $7.00 per share.  This represents more than a 100% move compared to the $3.45 close on Thursday.   What was more impressive was the $7.00 price target versus a $3.45 close before, indicating just over 100% upside.

Credit Suisse noted that Vical’s lead product Allovectin is in a Phase III trial for the treatment of metastatic melanoma but noted that it also has a pipeline of other vaccine product candidates. The firm’s discounted cash flow target is based solely on Allovectin, which the firm noted “makes Vical a high risk investment because Allovectin still needs to successfully complete Phase 3 and the FDA approval process.”  The firm went on to note impressive Phase II data with overall survival of chemo-naïve and experienced patients as being 18.8 months.  It further noted that the drug did even better in chemo-naïve patients with a median overall survival of 22.5 months versus 11.2 months from Bristol-Myers Squibb Company (NYSE: BMY) Yervoy+DTIC in chemo naïve patients. 

VIVUS, Inc. (NASDAQ: VVUS) was also started as “Outperform” with $15 target at Credit Suisse.  The firm noted the title “The Road to a New Obesity Drug Is Tough, but
It Ain’t Over ‘Til the…”  The firm believe that VIVUS’ weight loss pill Qnexa will be approved in the United States as a drug to treat obesity with a restricted label in the second quarter of 2012 and then will be approved in Europe in the third quarter of 2012.  Credit Suisse’s discounted cash flow based target price is driven entirely by Qnexa.  The firm went on to note, “which makes Vivus a high risk investment because our target price is dependent on US approval.”

Vical is up 5% at $3.62 on normal trading volume and VIVUS is up 4.5% at $9.92. Bristol-Myers Squibb Company (NYSE: BMY) is down 1.5% at $31.26 on the day.

JON C. OGG

The Next Blockbuster Drug (PFE, BMY, BAYRY, JNJ, SNY)

June 23, 2011 · Filed Under fda, Financial, Heart, R&D · Comment 

Against a backdrop of falling stock prices, Pfizer Inc. (NYSE: PFE) and Bristol-Myers Squidd company (NYSE: BMY) have bucked the trend of the day and both are seeing a rise in their share prices after reporting that “apixiban” has tested as being superior to and safer than the generic drug “warfarin.”   Both drugs are intended to aid in preventing strokes in patients with dangerously irregular heart rhythms.  “Apixiban” is the experimental blood thinner being developed by both Pfizer and Bristol Myers.  “Warfarin” is the generic version of Coumadin, whose patent expired more than 10 years ago.

The hope is that this will lead to another blockbuster drug with more than $1 billion in sales.  The timing couldn’t be better for the two companies as Big Pharma companies are generally facing an industry-wide patten cliff, where a number of significant pattens will soon expire.  As a result, less expensive and far-less-profitable generics will soon displace proprietary pharmaceuticals along with much off the revenues these products generate.  This has so far not managed to keep these companies from being able to offer extremely high dividends.

The news of apixiban’s successful tests negatively impacted the prices of companies manufacturing competing blood thinners.  Bayer AG (BAYRY.PK) and Johnson & Johnson (NYSE: JNJ ) are seeking FDA approval for “xarelto,” their own blood thinner, traded lower.  In mid-day activity, Bayer traded at $77.15, down 7.26%, while Johnson and Johnson traded at $64.85, down 1.85%. Sanofi-Aventis (NYSE: SNY) who partners with Bristol-Myers in co-marketing, the hugely successful blood thinner, “Plavix” traded down over 2% at $37.08. “Plavix” will lose its patent protection in the near future.

The successful tests of “apixiban” effectively make Bristol-Myers a double winner by compensating for the impending expiration of its proprietary position with a promising new blood thinner.  In mid-day activity, shares of Bristol-Myers traded up 5.4% at $29.25, while Pfizer traded up 2.1% at 20.72.  Shares of both companies are near their highs for the day.

Before today’s announcement, the consensus price target for Pfizer was $23.37 per share, giving the shares an implied upside a tad less than 13%.  With today’s gains, Bristol-Myers Squibb has essentially surpassed its posted consensus target price.  Keep in mind that unforeseen and significant new product introductions like “apixiban” have the potential of powering upside adjustments in consensus price targets, earnings and revenue estimates, and even in the overall bias.  The question is, how much of a game changer will “apixiban,” prove to be . . . not merely in “targets” but in realized revenues and profits.

Morgan Stanley has now boosted its rating on Bristol-Myers Squibb to Overweight and said they win from this much more than Pfizer due to relative size.

JON C. OGG

When Analysts Expect Shares to More Than Double (VICL, PRAN, BMY, AMGN)

April 26, 2011 · Filed Under analyst calls, Cancer · Comment 

We recently have picked back up on searching for ten-baggers in the field of biotechnology and those companies tied to a broader “BioHealth” sector.  Ten-baggers are those which can rise tenfold, or 1,000% from their lows, and these are generally measured from an extreme low in the shares.  Occasionally you do get to see a legitimate Wall Street analyst calling for a stock to more than double.  That is exactly what we are seeing this morning in shares of Vical Inc. (NASDAQ: VICL).  Canaccord Genuity initiated coverage with a “BUY” rating and it assigned a whopping $8.00 price target objective based mostly upon its Allovectin-7 as a potential malignant melanoma treatment.

Before we get too far into the Canaccord call, it was just recently that we issued a potential ten-bagger alert in Prana Biotechnology Ltd. (NASDAQ: PRAN).  It was after this note that a portfolio manager sent us an email as to why Vical was “his ten-bagger pick” in the space based in part on the belief that A-7 will get FDA approval after its results.  And, yes, he did disclose that he owned the position.  The portfolio manager’s biggest point is a true one: Prana may be a decade out, Vical is a 2011 to 2012 event.

Back to Canaccord Genuity… Vical closed at $3.25 on Monday and the 52-week trading range is $1.70 to $4.05.  What Canaccord Genuity did was issue a research report calling for almost 150% upside.  This is not unheard of, but calling for 100% upside in a formal research report is generally thought of as being extremely optimistic.  This call was for 146%. There are very few analysts which cover Vical at this time and the consensus price target is about $5.50 per share. 

OK, so almost 10% of that upside has already been spoken for.  Vical shares were up 9.5% at $3.52 on more than 1 million shares even right before Noon today.  Here is what Canaccord Genuity sees that the rest of us haven’t yet considered or caught on to as of yet:

  • Anticipation of appreciation going into A-7′s Phase III melanoma trial results maturing in the first half of 2012.
  • Bristol-Myers Squibb (NYSE: BMY) was referenced as a point for stand of care and as a recent approval by the FDA.  A7 is noted as having even better results, with a 7.5-year survival rate in some of its patients. 
  • A7 also had a lower adverse event-risk than Yevoy with positive survival data.  A-7 was said to absent of Grade 3/4 adverse events.
  • The firm now models $1 billion in combined US/EU sales by 2018.
  • Almost all of Vical’s market cap is based upon its A7 as an oncology asset, but the belief is that A7 will reflect well upon its entire vaccine platform.  The company’s valuation is believed to be back-stopped by the DNA-based vaccine technology platform.

There are of course some risks.  The obvious is that clinical trials could fail or that regulatory hurdles could arise, and there is also a risk that competition could change.  Canaccord further noted that Vical had $52 million in cash at the end of 2010 and that should be ample to fund clinical trials and operations into the second-half of 2012.

There is also an Amgen Inc. (NASDAQ: AMGN) reference here.  Canaccord’s team noted, “Data from a proof-of-concept trial evaluating Amgen’s newly acquired OncoVEX also supports immunotherapy potential in this indication.” Canaccord also gave a pipeline chart with the status of each candidate, shown by name, target, who the product partner is, and what stage these are in:

  • Allovectin-7 AnGes, Teva Phase 3
  • TransVax none Phase 2
  • HIV DNA vaccine none Phase 2
  • Malaria DNA vaccine none Phase 2
  • Ebola vaccine NIH Phase 1
  • H1N1 Pandemic Influenza virus US Naval Medical Research
  • Center collaboration Phase 1
  • H5N1 pandemic flu vaccine none Phase 1
  • SARS vaccine NIH Phase 1

Vical has a market cap of $255 million even after today’s move.  Biotech and biohealth companies typically trade at mulotiples of revenues rather than at fractions of revenues.  Analysts only see $21 million 2012 revenues, so that “multiples” is true today.  The difference is what happens if Vical can actually ramp up to that $1 billion in sales by 2018.  There could still be a lot more to this story, particularly when Vical gets the call for its virus vaccine prgram any time the government gets scared about a new potential pandemic outbreak like SARS, pandemic flu, and worse.

JON C. OGG

Top BioHealth Research Calls of the Week (MNKD, PDLI, ILMN, CLDA, MRK, PFE, LLY, BMY, ALXN, SVNT, AMGN)

January 22, 2011 · Filed Under analyst calls, fda, Financial · Comment 

There were some key research calls in biotech and biohealth shares this week.  Over in our “top five analyst calls of the week” at 24/7 Wall Street we noted how one firm came out in defense of MannKind Corporation (NASDAQ: MNKD) on its implosion this week and another call was highlighting the potential upside value that remains in PDL BioPharma, Inc. (NASDAQ: PDLI) despite its patent fight concerns.  There were many other standout calls though in analyst coverage this last week in biohealth:

Illumina Inc. (NASDAQ: ILMN) has remained impressive after having been one of our “Best of Big BioHealth in 2010″ and was also at the start of the year listed as “an overvalued biohealth names with peers.” This week brought an analyst duel.  Citigroup raised its rating to BUY from Hold and the new price target is $85.00 per share.  Thomson Reuters has a consensus price target of $66.87 and the Citi target appears to be the street-high price target.  Elsewhere, RBC Capital Markets lowered the rating to Sector Perform from Outperform due to valuation.  Illumina’s 52-week range is $34.25 to $71.07, and at $68.75 it has a market cap now of $8.6 billion.

Clinical Data Inc. (NASDAQ: CLDA) will be one to watch this coming week after the FDA approved its antidepressant drug to be sold under the brand name Viibyrd.  Shares closed at $15.03 on Friday but were much higher after the news and the 52-week trading range is $10.87 to $22.39.  What is interesting is that analysts already see peak sales above $2 billion as this antidepressant is believed to not interfere with sexual desire as much as in some rival drugs. The consensus price target is already $29.67 per Thomson Reuters data.

This week came a standout call in Big Pharma from Wells Fargo as the firm raised the sector to “Overweight.”  Wells Fargo raised Merck & Co. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) to Outperform ratings and also noted Eli Lilly & Co. (NYSE: LLY) and Bristol-Myers Squibb Company (NYSE: BMY) in the call.

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) closed the week out at $84.43 and has a 52-week range of $44.86 to $87.14.  There was an analyst duel this week.  Gleacher & Co. raised its rating to Buy while UBS cut its rating to Hold.

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) hit new 52-week lows this last week and closed at $10.20 versus a 52-week range of $10.16 to $23.46.  Its shares were downgraded to “Underperform” over at Bank of America Merrill Lynch after previous news in its business update of reports of batch failures with its new gout medication called Krystexxa.

Amgen Inc. (NASDAQ: AMGN) is set to report earnings on Monday and Thomson Reuters has estimates of $1.10 EPS and $3.8 billion in revenues; for the next quarter estimates are $1.31 EPS and $3.67 billion in revenues. At $56.97 shares are actually down slightly from 90-days ago and the 52-week range is $50.26 to $61.26.  This stock is getting toward its higher end of a 3 year trading band, so we expect that analyst will have to make some adjustments after earnings.  Thomson Reuters has an average price target above $65.00 currently.

At the end of December, we gave a list of Big Biotechs With teh Most Upside in 2011.

Those are definitely not all of the research calls of the week in biotech and biohealth names, but this was a fairly busy week.

Stay Tuned!

JON C. OGG

Diabetes & Insulin War About To Heat Up (MNKD, LLY, NVO, PFE, BMY, AZN, GERN)

January 6, 2010 · Filed Under Diabetes, fda, Financial, stem cells · 2 Comments 

MannKind Corp. (NASDAQ: MNKD) has not gone without its critics over the company’s inhaled insulin.  The company has an upcoming review that will be a make or break event for the company.  The company is about to face a potential do or die test next week as the FDA is set to decide the fate of the company’s inhaled insulin.  MannKind’s Afresa is designed to deliver a fast acting insulin that is supposed to be more effective than the injected products.  This would put the company in competition for insulin with Eli Lilly & Co (NYSE: LLY) and Novo Nordisk (NYSE: NVO) for their insulin delivery.

One of the biggest hurdles MannKind faces is that inhaled insulin products have been tried and tested by others, and they have failed or have fallen far short of the expectations set ahead of time.  Pfizer Inc. (NYSE: PFE) discontinued its Exubera as an inhalable insulin.

The FDA is set to make a ruling on Afresa’s approval by January 16, which means that the JAN-2010 CALL options may or may not expire before such ruling is made.  The FDA can always delay, and some reports hint at a later date now.
Read more

BioHealth Job Cuts Keep Coming (AZN, PFE, BSX, BMY, LLY, JNJ)

October 20, 2009 · Filed Under Uncategorized · Comments Off 

It used to be that pharmaceutical jobs and medical device maker jobs were among the best and most immune of all sectors in the economy.  They paid well, there was job security, the benefits were solid, stock option and retirement plans were always growing, and on.  That is still the case in many positions inside those companies.  But mergers, competition, efficiency, redundancy, and a new spending environment are changing this for many jobs in these once-safe sector.

Mergers have led to many “efficiencies” to be realized, and allowed “redundancies” (i.e. low-yield jobs and departments) to be eliminated.  And now there is an ongoing threat to the sector from Washington.  While the target has gone away from all of healthcare to health insurance, we are still seeing the announcement from major companies of more job cuts.  We have compiled a few of the latest found announcements, ad this is just a part of the whole pie.

AstraZeneca PLC (NYSE: AZN) is reportedly offering buyouts “to thousands of its near-5,000 workers” from its U.S. sales force.

Pfizer Inc. (NYSE: PFE) has outlined more job cuts from its Wyeth combination as part of a projected 15% cut to the combined Pfizer-Wyeth team.  What this number will ultimately come to is still unknown, and Pfizer’s head count had already fallen by over 6,000 to 75,400 at the end of last quarter.

Boston Scientific  (NYSE: BSX) had job cuts a couple years ago, and it appears that the job cuts may not be over.  Recent health reform legislation from the Senate Finance Committee was noted by its CEO as being an event which could potentially trigger another 1,000 to 2,000 job cuts.

Bristol-Myers Squibb Co. (NYSE: BMY) has been in an ongoing 10,000 layoff mode since last year, but in the last week came word that about 25% of its Abilify antipsychotic drug sales force after an evaluation from its co-marketing pact with Otsuka Corp.  These were recent cuts and are still unquantified.

Eli Lilly and Co. (NYSE: LLY) announced last month that it is targeting $1 billion in savings… with the elimination of up to 5,500 jobs total by some time in 2011.

This summer came the announcement from Johnson & Johnson (NYSE: JNJ) about its plan to cut up a range of 3,615 to to 4,800 jobs.  That is a small amount considering the number of deals it has made and considering it has 120,000 employees.

JON C. OGG
OCTOBER 20, 2009

BioHealth Earnings Floodgates Opening (BSX, BIIB, GILD, ISRG, PFE, DGX, SYK, AMGN, ELN, LLY, GENZ, STJ, BMY, MRK, SGP, ZMH)

October 16, 2009 · Filed Under Financial, General · Comments Off 

Next week is going to be the mother of all earnings reports for the BioHealth community.  We have included the key device companies as well in this calendar with the routine top drug and biotech companies.  As a reminder, these estimates may change between now and when some of the players report earnings.  In the screens for earnings we have the estimates included listed as the Thomson Reuters consensus figures.

MONDAY OCTOBER 19

  • Boston Scientific Corporation (NYSE: BSX) $0.14 EPS on $2.04 billion in revenues

TUESDAY OCTOBER 20

  • Biogen Idec Inc. (NASDAQ: BIIB) $1.04 EPS on $1.11 billion in revenues
  • Gilead Sciences    Inc. (NASDAQ: GILD) $0.67 EPS on $1.76 billion in revenues
  • Intuitive Surgical, Inc. (NASDAQ: ISRG) $1.46 EPS and $256.44 million in revenues
  • Pfizer Inc. (NYSE: PFE) $0.48 EPS and $11.4 billion in revenues
  • Quest Diagnostics Inc. (NYSE: DGX) $0.96 EPS and $1.89 billion in revenues
  • Stryker Corp. (NYSE: SYK) $0.69 EPS and $$1.62 billion in revenues

WEDNESDAY, OCTOBER 21

  • Amgen Inc. (NASDAQ: AMGN) $1.27 EPS and $3.79 billion in revenues
  • Elan Corporation, plc (NYSE: ELN) -$0.13 EPS on $285.18 million in revenues
  • Eli Lilly & Co. (NYSE: LLY) $1.01 EPS and $5.4 billion in revenues
  • Genzyme Corporation (NASDAQ: GENZ) $0.44 EPS and $1.11 billion in revenues
  • St. Jude Medical, Inc. (NYSE: STJ) $0.58 EPS and $1.16 billion in revenues

THURSDAY, OCTOBER 22

  • Bristol-Myers Squibb (NYSE: BMY) $0.51 EPS and $5.5 billion in revenues
  • Merck & Co., Inc. (NYSE: MRK) $0.83 EPS and $6 billion in revenues
  • Schering-Plough    Corporation (NYSE: SGP) $0.39 EPS and $4.45 billion in revenues
  • Zimmer Holdings Inc. (NYSE: ZMH) $0.86 EPS and $953.6 million in revenues

JON C. OGG
OCTOBER 16, 2009

BioHealth’s Top Stock Moves (AMLN, BMY, DNDN, DEPO, MRNA, ONXX)

October 12, 2009 · Filed Under Cancer, dendreon, M&A · Comments Off 

Some of today’s top movers in biotech and the world of BioHealth are Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Bristol-Myers Squibb Co. (NYSE: BMY), Dendreon Corporation (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), MDRNA, Inc. (NASDAQ: MRNA), and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX).

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) has seen little reaction after an activist investors has exited from the position in Amylin.  A weekend SEC filing showed that Eastbourne Capital has liquidated its Amylin stake after having previously held a 9.5% stake.  Reports put the reason as frustration with management.  The positive read is that this one will no longer have at least one group publicly pushing it.  And the bad is that this is a show of force of a loss of confidence.  Shares are effectively flat at $14.20.

Bristol-Myers Squibb Co. (NYSE: BMY) is trading higher this morning after Goldman Sachs listed it as one of its top candidates for a drug merger out there.  Be advised that after a 1.2% gain to $22.75 today this one has a market cap of some $45 billion.  Even if a billion isn’t what it used to be and even if a foreign buyer might perceive a 20% currency discount opportunity today, that is a very large number.

Dendreon Corporation (NASDAQ: DNDN) is running again on new solid board member additions to help it transition from an R&D company to a manufacturing company.  These are Ian Clark, the CEO of Roche’s Genentech unit, and Pedro Granadillo, a former Eli Lilly (LLY) manufacturing executive.  These are viewed as top brass to help the company transition from pre-revenue into a revenue generator (when and if its PROVENGE gets approved).  Shares are up almost 8% at $29.58 on over 3 million shares as of 11:30 AM EST.

DepoMed Inc. (NASDAQ: DEPO) has been hit very hard on mixed news that its Phase III clinical data for its menopausal hot-flash treatment Serada was a disappointment. The study for hot flashes drug met only 1 goal at 12 weeks.  Despite the results, Depomed remains hopeful about the program and said it plans to discuss these results with the FDA.  It seems as though that traders are shooting DepoMed first and may or may not ask questions later.  Around 11:30 AM EST we have seen 6.9 million shares, and DepoMed is down over 38% at $3.90.

MDRNA, Inc. (NASDAQ: MRNA) is trading up substantially higher on news that UsiRNA reduces tumor growth in vivo, where the company showed data demonstrating continued progress in the advancement of its oncology program. MDRNA’s UsiRNAs is delivered by the company’s DiLA2 platform that showed subsequent reductions in tumor growth in models of liver and bladder cancer.  Shares are up 29% at $1.60 on over 5.5 million shares.

Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) has been one of the long-standing stocks in the rumor mill that has been noted as a possible buyout candidate.  Today the company made a deal of its own and shares are up despite the notion that acquirers usually trade off.  Onyx signed a definitive agreement to acquire Proteolix, Inc., a privately held biotech focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.  The deal is valued at $276 million, but could ultimately end up being worth some $851 million.  Onyx shares are up 7% at $28.81 on over 3.3 million shares.

JON C. OGG
October 12, 2009
Price snapshots all taken as of 11:30 AM EST

Seattle Genetics' Boosted Secondary… Takeover Defense? (SGEN, BMY, MEDX, BAY, CRGN, PGNX, AZN)

August 12, 2009 · Filed Under Cancer, M&A, R&D · Comments Off 

Seattle Genetics, Inc. (NASDAQ: SGEN) is one of those companies in the world of biotech and biohealth which some have believed would be an ultimate takeover target.  The issue is that some companies either do not have enough funding on their own to secure a deal under the terms they would prefer.  Other companies want to grow and thrive on their own in the quest to become the next mega-blockbuster producer on the block.  So the news of an offering of common stock from Seattle Genetics, Inc. would now put the company in the second category, or so it may seem.

Seattle Genetics priced a secondary offering of 11,000,000 shares of common stock at $10.75 per share. The gross proceeds from the sale are expected to be approximately $118.2 million and should close on or about August 17, 2009.   The good news is that all of the shares in the offering are being sold by Seattle Genetics.  The other bit of good news is that the demand must have been strong.  The announcement was made Monday that it would sell 9 million shares, yet this pricing is for 11 million shares.

The company said that the use of funds will be used to fund R&D, including manufacturing activities and clinical trials for its proprietary product candidates, build-out of a commercial infrastructure and for general corporate purposes, including working capital.

The company also has a very high profile group of companies as the underwriters.
J.P. Morgan and Goldman Sachs are the joint book-running managers;  Needham, Oppenheimer, RBC Capital Markets, and William Blair are all listed as the co-managers of the offering.  The underwriters have a 30-day option to purchase up to 1,650,000 additional shares of common stock to cover over-allotments.

Back in July this stock was under $10.00.  Then came several developments.  It reported earnings, Bristol-Myers Squibb (NYSE: BMY) announced the acquisition of Medarex (NASDAQ: MEDX), then the company announced the initiation of Phase II trials of brentuximab vedotin (SGN-35) for lymphoma.  Then this week came the announcement that Seattle Genetics had achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune, LLC, a wholly owned subsidiary of AstraZeneca, after MedImmune’s initiation of a phase I clinical trial of MEDI-547 for solid tumors.

Seattle Genetics has an exclusive worldwide collaboration agreement with Roche’s Genentech for the development and commercialization of dacetuzumab (SGN-40). Under the agreement, Genentech paid us $60 million upfront, and has agreed to pay potentially more than $800 million in milestones and escalating double-digit royalties starting in the mid-teens on annual product sales. In addition, Genentech funds research, development, manufacturing and commercialization costs. Seattle Genetics  also has an option for co-promotion rights on dacetuzumab in the U.S.

The company has licensed its antibody-drug conjugate (ADC) technology to Genentech, Bayer (NYSE: BAY), CuraGen Corp. (NASDAQ: CRGN), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Daiichi Sankyo, AstraZeneca’s (NYSE: AZN) MedImmune, and Takeda’s Millennium.  These collaborations all involve upfront cash payments, milestones and royalties on net sales of products incorporating Seattle Genetics’ ADC technology. The licensees are responsible for development, manufacturing and commercialization of any ADC product candidates that result from the collaborations.

Another deal is in place as a co-development agreement with Agensys, a wholly-owned subsidiary of Astellas Pharma. In this the companies will jointly develop ADC products where Agensys provides proprietary targets and monoclonal antibodies to be utilized with Seattle Genetics’ proprietary ADC technology. The companies share research and development costs on up to two ADC products, and share equally in any profits.

Shares closed down over 7% at $10.99 in anticipation of the secondary offering and the stock’s 52-week range is $6.81 to $13.40.  The company has been public since 2001 and has spent the bulk of the time from early 2007 to now trading in a range of $8.00 to $12.00.  Its market before the effects of any secondary offering was $947 million after Tuesday’s drop. SGEN is also a stock with a high short interest: in mid-July it had over 5.5 million shares in the short interest, about 13.9 days worth of average trading volume.

This is still very much a research and development stage company.  Analysts are only looking for about $38 million in revenues for 2009 and about $54 million in revenues in 2010.  Until its products are closer to commercialization, losses are expected well beyond this year and next.

JON C. OGG

Diabetes Drug War Heats Up (NVO, AMLN, LLY, MNKD, PFE, SPEX, VVUS, GNBT, BMY, AZN, ARNA, GERN, STEM, OREX, HDIX, PODD)

August 10, 2009 · Filed Under Cancer, Diabetes, M&A, obesity, stem cells · Comments Off 

Over the last couple of weeks, there has been quite a bit of new data in the drug war in the fight against diabetes.  New studies have been updated, earnings projections have been made, FDA dates have been telegraphed and more.  While these are still far short of ultimate cures, the war against diabetes may have many new or improved treatments out sooner rather than later.  We originally discussed one or two of the key upcoming treatments pending for the eight major diseases and conditions as “the next $170 billion opportunity” and this is a much deeper dig into that broad initiation.  We have included many of the recent developments in the potential treatments for obesity as well, considering that Type II diabetes and obesity are frequently conditions tied directly to each other.

According to the Journal of Health Affairs, the figure on obesity for Americans is a whopping $147 billion per year in total medical costs. This comes to 10% of all healthcare spending. The figure from the U.S. Centers for Disease Control was some $116 billion spent domestically on treating diabetes in 2007.  As this is a lengthy bit, we have not included some of the other treatments that have been in use or that were recently flagged because of reports of higher chances of cancer rates associated by the long-term use of these.

FDA & IMMEDIATE ACTION

There is a new diabetes hopeful that is supposed to be coming sooner rather than later.  Novo Nordisk (NYSE: NVO) reported a 21% gain in earnings in the last week and said that it expects the FDA to make a decision on its next-generation diabetes drug Victoza (liraglutide) in a matter of weeks. The company’s CFO and CEO both indicated that the Danish company does expects a positive response from the FDA and we heard a August to September expectation. Novo Nordisk has already launched Victoza in England, Germany and Denmark last month and expects to release it in other European Union countries throughout 2009 and into 2010.  The benefit is that this one doesn’t risk pushing blood glucose levels to counts which are dangerously low and it also helps users lose weight.  Novo Nordisk said it has priced Victoza competitively with Byetta from Amylin Pharmaceutical, Inc. (NASDAQ: AMLN) and Eli Lilly (NYSE: LLY).  After the earnings and after shares were still close to 52-week highs, we saw analyst downgrades on Friday for Novo Nordisk by both UBS and by J.P. Morgan.

The drug still expected the next big new release with Blockbuster potential is an inhalable insulin from MannKind Corp. (NASDAQ: MNKD).  Afresa is to be its name. Despite past woes of inhalable insulin, MannKind shares were hitting 52-week highs in June and its shares are still up 20% from three months ago.  A late-stage study showed that Afresa’s performance was similar to injectable insulin.  The company recently sold a 7.4 million shares secondary offering to raise cash for this launch, and its CEO took 1 million shares of the offering.  The thought was that MannKind would secure a partner for marketing and development, but the recent stock offering gives it more internal options ahead of what is believed to be a Spring-2010 FDA approval action.  Pfizer Inc (NYSE: PFE) has been thought of as a partner as it moved Exubera inhaled-insulin patients to MannKind’s experimental product. The two companies had been partners until Pfizer pulled Exubera from the market in 2007.

There is also a huge opportunity for the once per week dosing.  We are not yet convinced that this can be a universal next generation treatment, however this might be fine for many of the lower grade cases if you can refer to any diabetes cases as lower grade.  Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Eli Lilly (NYSE: LLY) and Alkermes Inc. (NASDAQ: ALKS) have had a recent New Drug Application accepted by the FDA for review. Exenatide is an investigational sustained release medication for type 2 diabetes that would be injected once per week and is the active ingredient in BYETTA.  We are not alone in this thought, but Amylin is a company which many have thought would be acquired for years now when considering the link of diabetes and obesity.

VIVUS, Inc. (NASDAQ: VVUS) has a substantial shot here with Qnexa, its  Type 2 diabetes treatment through weight loss assistance.  The stock recently came off on worries of its risk factor language that may have to be disclosed, but it showed a 9.4% weight loss or over 20 pounds observed in patients.  The DM-230 study was a 56-week study assessing the impact of Qnexa on glycemic management in 130 obese patients.  The 10-site study was comprised of 90 females and 40 males with an average age of 50 who had Type 2 diabetes, and a majority of the patients had been diagnosed with diabetes for more the five years and were taking two or more oral diabetes medications.  In the phase II and phase III clinical trials, Qnexa demonstrated glycemic control, significant weight loss, and an improvement in cardiovascular risk factors.  VIVUS is also presenting data at a brokerage firm conference this coming Thursday.  The company’s market cap is still just under $500 million and its most recent balance sheet had north of $144 million in cash and equivalents with very little long term debt.

Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca (NYSE: AZN) have recently received FDA approval for Onglyza as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. This Onglyza is a once-daily dipeptidyl peptidase-4 (DPP4) inhibitor that can be used in combination with commonly prescribed anti-diabetic medications or on a standalone basis as a monotherapy to significantly reduce glycosylated hemoglobin levels.

MORE OBESITY CANDIDATES COMING

Several biotechnology companies are working on the next wave of obesity candidates, as noted above in VIVUS’s Qnexa.  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) has Lorcaserin, Orexigen Therapeutics, Inc. (NASDAQ: OREX) has Contrave, and Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has pramlintide.  Orexigen’s Contrave has completed phase III trials and our time line for when the company will file for approval is in early 2010. The company is presenting data this Thursday at the Canaccord Adams Global Growth Conference.  VIVUS’s Qnexa is currently in two phase III programs with a new drug application expected around the middle of 2010.   Amylin’s pramlintide and metreleptin are currently in phase IIb.

We have the expectation that Arena will have a first-mover advantage with an NDA planned before the end of 2009.  Certainly, any delays or advances could change the status of the front-runner category leadership.  Arena’s near-term catalyst is the release of the phase III BLOSSOM data out in September 2009, which will be used as part of a supplemental NDA in late 2009 or into 2010.  This still leaves a year or more for final FDA action from now.  Arena shares surged in late-July after reporting that its obesity results met the three endpoints.

STEM CELLS

Stem Cell therapy offers a huge promise, but so far that looks to be years out and the promise is actually more of a hope for the time being.  Geron Corporation (NASDAQ: GERN) is in the research stage of using stem cells in evaluation of Type 1 diabetes.  The exact level of this study is not as far as along as some of its cancer and spinal studies, but this is one of the few stem cell companies that have dedicated part of their mission to diabetes.  StemCells Inc. (NASDAQ: STEM) also has a Pancreatic Program concentrating its efforts on Type-I diabetes.  Its goals are to identify, isolate, and culture pancreatic stem and progenitor cells, and to test their therapeutic potential.

While we at BioHealthInvestor would love to hold hope and promise for stem cells, we would not be hoping for stem cell treatments any time in the near future.  While some positive notions have been noted in the stem cell sector, the National Institute of Health noted, “Over the past several years, doctors have attempted to cure diabetes by injecting patients with pancreatic islet cells—the cells of the pancreas that secrete insulin and other hormones. However, the requirement for steroid immunosuppressant therapy to prevent rejection of the cells increases the metabolic demand on insulin-producing cells and eventually they may exhaust their capacity to produce insulin. The deleterious effect of steroids is greater for islet cell transplants than for whole-organ transplants. As a result, less than 8 percent of islet cell transplants performed before last year had been successful.”

Read more

Next Page »

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed